Search

Your search keyword '"Richert, J.R."' showing total 8 results
Start Over Author "Richert, J.R."
8 results on '"Richert, J.R."'

2. Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials

Author

Goodkin, D.E., primary, Priore, R.L., additional, Wende, K.E., additional, Campion, M., additional, Bourdette, D.N., additional, Herndon, R.M., additional, Fischer, J.S., additional, Jacobs, L.D., additional, Cookfair, D.L., additional, Rudick, R.A., additional, Richert, J.R., additional, Salazar, A.M., additional, Granger, C.V., additional, Simon, J.H., additional, Alam, J.J., additional, Bartoszak, D.M., additional, Braiman, J., additional, Brownscheidle, C.M., additional, Coats, M.E., additional, Cohan, S.L., additional, Dougherty, D.S., additional, Kinkel, R.P., additional, Mass, M.K., additional, Munschauer III, F.E., additional, Pullicino, P.M., additional, Scherokman, B.J., additional, Weinstock-Guttman, B., additional, and Whitham, R.H., additional

Published
1998
Full Text
View/download PDF

6. Serum IL-17F does not predict poor response to IM IFN-1a in relapsing-remitting MS

Author

Bushnell, S.E., Zhao, Z., Stebbins, C.C., Cadavid, D., Buko, A.M., Whalley, E.T., Davis, J.A., Versage, E.M., Richert, J.R., Axtell, R.C., Steinman, L., and Medori, R.

Abstract

There is a significant unmet need for serum biomarkers in relapsing-remitting multiple sclerosis (RRMS) that are predictive of therapeutic response to disease-modifying therapies. Following a recent Stanford study which reported that pretreatment levels of serum interleukin (IL)-17F could predict poor response to interferon- (IFN) therapy, we sought to validate the finding using samples from a large clinical trial.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results